ALNYLAM PHARMACEUTICALS, INC. Induced Conversion of Convertible Debt Expense
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Induced Conversion of Convertible Debt Expense of $39.10 million for the 12-month period ending 2025-12-31, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InducedConversionOfConvertibleDebtExpense · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. induced conversion of convertible debt expense for the quarter ending 2025-12-31 was -$46.00K.
- ALNYLAM PHARMACEUTICALS, INC. induced conversion of convertible debt expense for the quarter ending 2025-09-30 was $39.15M.
- ALNYLAM PHARMACEUTICALS, INC. induced conversion of convertible debt expense for the quarter ending 2024-12-31 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. induced conversion of convertible debt expense for the quarter ending 2024-09-30 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. induced conversion of convertible debt expense for fiscal 2024 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. induced conversion of convertible debt expense for fiscal 2023 was $0.00.
| Period end | Induced Conversion of Convertible Debt Expense 1 month | Induced Conversion of Convertible Debt Expense 3 month | Induced Conversion of Convertible Debt Expense 6 month | Induced Conversion of Convertible Debt Expense 9 month | Induced Conversion of Convertible Debt Expense 12 month | Induced Conversion of Convertible Debt Expense 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | -$46.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2026-07-30 | $39.10M derived: sum of 2 quarters · filed 2026-07-30 | $39.10M 10-Q · filed 2026-07-30 | $42.47M 10-K · filed 2026-02-12 | ||
| 2025-09-30 | $39.10M 10-K · filed 2026-02-12 | $39.15M 10-Q · filed 2025-10-30 | $39.15M 10-Q · filed 2025-10-30 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $0.00 derived: sum of 2 quarters · filed 2026-02-12 | $0.00 10-K · filed 2026-02-12 | |||
| 2024-09-30 | $0.00 10-Q · filed 2025-10-30 | $0.00 10-Q · filed 2025-10-30 | ||||
| 2023-12-31 | $0.00 10-K · filed 2026-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |